And it has all happened because of a virus that caught the world unprepared.
The WHO report released today states that total deaths as reported by national health authorities attributable to COVID-19 don’t take into account excess mortality, or as it describes, “the mortality above what would be expected based on the non-crisis mortality rate.”
Excess mortality is not a measure that can easily be gleaned from across the planet. Why not? Because not all countries measure mortality at the same pace and in the same way. Data reporting techniques differ. Some countries don’t even measure at all. This makes calculating excess mortality problematic.
Scientists have uncovered changes in neurological structure that could underlie the autism spectrum disorder known as Pitt Hopkins syndrome, thanks to the help of lab-grown brains developed from human cells.
Furthermore, the researchers were able to recover lost genetic functions through the use of two different gene therapy strategies – hinting at the possibility of treatments that could one day give those with the condition new options in improving their quality of life.
Pitt Hopkins syndrome is a neurodevelopmental condition stemming from a mutation in a DNA-management gene called transcription factor 4 (TCF4). Classed on the autism spectrum on account of its severe impact on motor skills and sensory integration, it’s a complex condition that presents with a range of severities.
It’s not often that a failed clinical trial leads to a scientific breakthrough.
When patients in the UK started showing adverse side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back through the data and worked with patient samples to see what went wrong.
Their findings, published recently in Nature, provide critical clues to why many immunotherapies trigger dangerous side effects—and point to a better strategy for treating patients with solid tumors.
Reimagining A Healthier Future for All — Dr. Pat Verduin PhD, Chief Technology Officer, Colgate, discussing the microbiome, skin and oral care, and healthy aging from a CPG perspective.
Dr. Patricia Verduin, PhD, (https://www.colgatepalmolive.com/en-us/snippet/2021/circle-c…ia-verduin) is Chief Technology Officer for the Colgate-Palmolive Company where she provides leadership for product innovation, clinical science and long-term research and development across their Global Technology Centers’ Research & Development pipeline.
Dr. Verduin joined Colgate Palmolive in 2007 as Vice President, Global R&D. Previously she served as Vice President, Scientific Affairs, for the Grocery Manufacturers Association, and from 2000 to 2006, she held the position of Vice President, Research & Development, at ConAgra Foods.
Dr. Verduin started her career with 17 years at Nabisco, serving in multiple roles, including plant manager and scientist. She earned her undergraduate degree from the University of Delaware, holds an MBA from Fairleigh Dickinson University and a PhD in Food Science from Rutgers University.
Colgate-Palmolive Company (https://www.colgatepalmolive.com/) is an American multinational consumer products company specializing in the production, distribution and provision of household, health care, personal care and veterinary products, with a mission of re-imagining a healthier future for all people, their pets and our planet.
A growing group of startups and established logistics firms have created a multi-billion-dollar industry applying artificial intelligence and other cutting-edge… See more.
LONDON, May 3 (Reuters) — Over the last two years a series of unexpected events has scrambled global supply chains. Coronavirus, war in Ukraine, Brexit and a container ship wedged in the Suez Canal have combined to delay deliveries of everything from bicycles to pet food.
In response, a growing group of startups and established logistics firms has created a multi-billion dollar industry applying the latest technology to help businesses minimize the disruption.
Interos Inc, Fero Labs, KlearNow Corp and others are using artificial intelligence and other cutting-edge tools so manufacturers and their customers can react more swiftly to supplier snarl-ups, monitor raw material availability and get through the bureaucratic thicket of cross-border trade.
In removing cilia from human pluripotent stem cells, Freedman and his colleagues sought to understand what would happen in their subsequent transformation into tissues and organoids. As it happened, the cilia-free stem cells appeared normal but were unable to fully realize new forms.
“It was surprising to me that, at a certain point after they were turning into tissues, they seemed to break down,” Freedman said. “They struggled to transform into anything sophisticated. I think one lesson from this is that the cilia help get cells through their final stage of development.”
It was first reported in 2000 that PKD could stem from defects in cilia, but the mechanism of damage that causes cysts to form has escaped scientists. By creating cilia-free stem cells that harbor disease, Freedman said, the researchers now have a framework with which to test and compare molecular actions in the cilia.
Estimates put this industry’s worth at a staggering $610 billion by 2025. 😳
The Renaissance philosopher Montaigne quipped that “death has us by the scruff of the neck at every moment.” He could have added: until, finally, it strangles us. But what if we knew how to escape death’s chokehold? What if we could avoid death and live forever?
Immortality might seem like the stuff of science fiction, yet it’s increasingly becoming the focus of real science. In 2013, Google launched Calico, a biotech firm whose objective is to “solve” death. PayPal co-founder Peter Thiel, meanwhile, has pledged to “fight” death. And last year, it was reported Amazon chairman Jeff Bezos had invested in Altos Labs, a company that plans to “rejuvenate” cells in order to “reverse disease.” (Bezos owns The Washington Post.)
Tesla Giga Shanghai has resumed over 80% production along with several other companies, according to Chinese official Zhang Hongtao — the chief engineer of the Shanghai Economics and Information Technology Commission.
China created a “whitelist” to support companies resuming production and minimize the impact of Covid along the supply chain. As of Saturday, April 30, approximately 1,854 companies have made it onto the whitelist, including Tesla, and are authorized to resume work.
During a press conference, Zhang stated that Shanghai created a second list of 1,188 companies that can resume work. According to the Global Times, the companies fall into the automobile manufacturing, equipment manufacturing, and biomedicine sector.
